World Health Organization member states are in a two-week negotiating session on the unfinished pathogen-access and benefit-sharing system connected to the WHO Pandemic Agreement. The hybrid meeting in Geneva runs from November 2 through 13, with opening and closing sessions webcast. Its task is to develop an annex that links the sharing of pathogens and genetic sequence information with access to benefits such as vaccines, diagnostics and treatments.
The World Health Assembly adopted the main Pandemic Agreement in May 2025, but the instrument is not yet open for signature. Member states assigned an intergovernmental working group to complete the Pathogen Access and Benefit Sharing annex, usually called PABS. WHO's implementation outline says the full agreement will move to signature and national ratification after the annex is adopted. Entry into force requires ratification by 60 countries.
The current session is the group's ninth formal meeting. WHO has posted a provisional agenda, programme of work, draft annex text and written stakeholder statements. The stated deadline is consideration by the Eightieth World Health Assembly in May 2027, although earlier action could occur through a special session. November's schedule gives delegations ten working days to reduce remaining differences, but a meeting calendar does not guarantee a final agreement.
PABS is meant to address a basic exchange problem. Faster access to pathogen material and sequence information can support surveillance and development of countermeasures. Countries that share information also want predictable and equitable access to the products and other benefits created from it. The annex must define obligations, recipients, timing and oversight clearly enough that laboratories, governments and manufacturers can use the system before and during an emergency.
The debate is not simply about transferring a sample. Genetic data can move digitally, products require manufacturing capacity, and an outbreak may demand decisions before normal procurement channels can respond. A workable annex therefore must connect scientific access, public-health need and benefit allocation without discouraging timely reporting. It also must operate alongside existing national laws, the amended International Health Regulations and other research or biological-material arrangements.
The agreement does not give the WHO authority to impose lockdowns or vaccination mandates on countries. National governments retain control over domestic health measures and decide whether to sign and ratify under their constitutional processes. The WHO secretariat supports negotiations and future coordination, while states create the legal commitments. That division is important when evaluating claims that the agreement transfers general emergency powers to the organization.
Adoption of an annex would be a milestone rather than immediate implementation everywhere. Countries would still need to sign, ratify and align domestic systems; the agreement would then establish a Conference of the Parties for ongoing governance. Manufacturers, laboratories and public agencies would need operational rules, reporting channels and supply arrangements. The effectiveness of the system would depend on whether those pieces work during an actual threat, not only on the text negotiated in Geneva.
The next verifiable milestones are any revised draft issued during the session, the closing report on November 13 and the document ultimately sent to the World Health Assembly. Until those records appear, the talks should be described as active negotiations rather than a completed settlement. Their significance lies in trying to join rapid scientific cooperation with a defined benefit-sharing mechanism, the part of the post-COVID framework that member states have not yet finished.
Primary sources: WHO ninth negotiating-session overview; WHO meeting documents and provisional agenda; WHO Pandemic Agreement implementation overview. Reviewed November 3, 2026. Development: Negotiating session runs November 2–13, 2026.